Biodesix Inc (OQ:BDSX)

Business Focus: Medical & Diagnostic Laboratories

Apr 09, 2024 05:00 pm ET

Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. These presentation

Apr 05, 2024 07:17 am ET

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities purchase agreements for a concurrent private placement of

Mar 25, 2024 06:00 am ET

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.

Mar 01, 2024 06:00 am ET

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023).

Feb 26, 2024 06:00 am ET

Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the TD Cowen 44th Annual Health Care Conference, which will be held from March 4-6, 2024.

Feb 16, 2024 06:00 am ET

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2023 before the open of trading on Friday, March 1. Biodesix’s management will host a conference call and webcast to discuss its financial result

Nov 14, 2023 06:00 am ET

Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+™ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient’s upper arm.

Nov 09, 2023 06:00 am ET

Biodesix to Participate in Two Upcoming Investor Conferences in November

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences:

Nov 07, 2023 04:01 pm ET

Biodesix Announces Third Quarter 2023 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update.

Oct 24, 2023 06:00 am ET

Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7. Biodesix’s management will host a conference call and webcast to discuss its financial results and

Oct 03, 2023 06:00 am ET

Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi. These presentations will provide new insight on the clinical utility and real-world impact of the Nodify CDT and Nodify XL2 tests in the comprehensive management of lung nodules.

Sep 07, 2023 06:00 am ET

Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that two abstracts will be presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Lung Conference on Lung Cancer (WCLC). The first presentation showcases a new analysis of the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects, NCT03289780) demonstrating the ability of the VeriStrat host immune classifier

Sep 05, 2023 06:00 am ET

Biodesix to Participate in Two Upcoming Investor Conferences in September

Aug 22, 2023 06:00 am ET

Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that a new analysis from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2 Test NCT03766958) will be presented at the 6th Annual Conference of the American Association for Bronchology and Interventional Pulmonology (AABIP). The data will be presented by principal investigator of the ORACLE study, Michael Pritchett, DO, MPH, on Thursday, Aug. 24, 2023 in a live poster presenta

Aug 07, 2023 04:01 pm ET

Biodesix Announces Second Quarter 2023 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2023 and provided a corporate update

Aug 01, 2023 06:00 am ET

Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the Canaccord Genuity 43rd Annual Growth Conference, which will be held from August 7-10, 2023.

Jul 24, 2023 06:00 am ET

Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the second quarter ended June 30, 2023 after the close of trading on Monday, August 7. Biodesix’s management will host a conference call and webcast to discuss its financial result

Jul 12, 2023 06:00 am ET

Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test [NCT03766958]) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures. The data was

Jul 06, 2023 09:11 am ET

Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has designated the Nodify CDT® Test as an Advanced Diagnostic Laboratory Test (ADLT) effective June 30, 2023.

Jun 27, 2023 06:00 am ET

Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) has completed enrollment of 5,000 p

Jun 01, 2023 06:00 am ET

Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations.

May 31, 2023 06:00 am ET

Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at William Blair’s 43rd Annual Growth Stock Conference, which will be held from June 6-8, 2023.

May 25, 2023 06:00 am ET

Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules. The posters, presented May 8-9, 2023, highlighted potential cost savings in both Medicare and commercially insured patient populations with use of the tests.

May 24, 2023 06:00 am ET

Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors

Biodesix, Inc. a leading diagnostics company, is proud to announce that its Chief Financial Officer, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors. As a seasoned executive with extensive experience in the life sciences sector, Ms. Harper Cowie's expertise will play a crucial role in driving the growth and development of Colorado's thriving life sciences community. In joining the CBSA board, Ms. Harper Cowie will collaborate with fellow industry leaders to bolster the supportive ecosystem for life sciences companies throughout the state.

May 18, 2023 07:00 am ET

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24, 2023, in Washington, DC.

May 11, 2023 04:01 pm ET

Biodesix Announces First Quarter 2023 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the first quarter ended March 31, 2023 and provided a corporate update.

Apr 27, 2023 06:00 am ET

Biodesix to Report First Quarter 2023 Financial Results on May 11, 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for first quarter ended March 31, 2023 after the close of trading on Thursday, May 11. Biodesix’s management will host a conference call and webcast to discuss its financial results an

Mar 06, 2023 06:00 am ET

Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the fourth quarter and year ended December 31, 2022 (fiscal 2022) and provided a corporate update.

Feb 28, 2023 06:00 am ET

Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will participate in a fireside chat and host in-person 1x1 investor meetings at Cowen’s 43rd Annual Healthcare Conference being held from March 6-8, 2023.

Feb 21, 2023 06:00 am ET

Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2022 before the open of trading on Monday, March 6. Biodesix’s management will host a conference call and webcast to discuss its fina

Dec 19, 2022 06:00 am ET

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Healt

Dec 16, 2022 04:01 pm ET

Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company’s Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating,

Dec 12, 2022 06:00 am ET

Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the Company was named the leading Proteomics Solutions Company in the U.S. by

Nov 21, 2022 04:01 pm ET

Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the closing of its underwritten public offering of 35,075,000 shares of its common stock at a price to the public of $1.15 per share, including the exercise in full by the underwriter of its option to purchase up to an additio

Nov 17, 2022 12:26 am ET

Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions. The gross proceeds to Biodesix from the offeri

Nov 16, 2022 04:05 pm ET

Biodesix Announces Proposed Public Offering of Common Stock

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. In connection with the offering, Biodesix

Nov 16, 2022 04:01 pm ET

Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and direc

Nov 10, 2022 09:00 am ET

Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Wallace Akerley, MD, medical oncologist at the University of Utah Huntsman Cancer Institute, will present new interim data from the large multi-center prospective observational registry study INSIGHT (Clinical Effectiveness

Nov 03, 2022 06:00 am ET

Biodesix Announces Third Quarter 2022 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for third quarter ended September 30, 2022 and provided a corporate update.

Oct 20, 2022 06:00 am ET

Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the third quarter ended September 30, 2022 before the open of trading on Thursday, November 3. Biodesix’s management will host a conference call and webcast to discuss its financia

Oct 17, 2022 06:00 am ET

Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the award of a U.S. Federal Supply Schedule contract which includes the Veterans Health Administration providing care for U.S. Veterans and Military Health System providing care for active-duty service members and their famili

Oct 12, 2022 06:00 am ET

Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participa

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three data presentations will occur at the CHEST 2022 Annual Meeting which will be held live and in-person for the first time since 2019. Presentations will include a sub-group analysis of data from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test - ORACLE [NCT03766958]) demonstrating that the Nodify XL2 test has equivalent performance in identifying patients with benign nod

Oct 11, 2022 06:00 am ET

Biodesix Announces Preliminary Revenue for Third Quarter 2022

Biodesix, Inc. (NASDAQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report third quarter 2022 total revenue to be in the range of $10.6 million to $11.2 million, representing growth of 62% to 71% over the third quarter 2021. The strength in the third quarter 2022 total revenue reflects continued growth in the Company’s core lung diagnostic testing. The financial results included in this release pertaining to the third quarter 2022 are preliminary, subject to completion of internal procedures and review.

Sep 06, 2022 06:00 am ET

Biodesix to Participate in Two Upcoming Investor Conferences in September

Aug 09, 2022 06:00 am ET

Biodesix Named a Top 100 Healthcare Technology Company of 2022

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has been recognized in the

Aug 04, 2022 06:00 am ET

Biodesix Announces Second Quarter 2022 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for second quarter ended June 30, 2022 and provided a corporate update.

Aug 03, 2022 06:00 am ET

Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.

Jul 20, 2022 06:00 am ET

Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Tr

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Young Kwang Chae, MD, MPH, MBA, Associate Professor of Medicine (Hematology and Oncology) Feinberg School of Medicine, Northwestern University will present the results of a retrospective analysis at the IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC2022) on August 8, 2022 in Vienna, Austria.

Jul 19, 2022 06:00 am ET

Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4. Biodesix’s management will host a conference call and webcast to discuss its financial resu

Jun 07, 2022 06:00 am ET

Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, has provided coverage for the Nodify CDT® lung nodule test.

Jun 03, 2022 06:00 am ET

Biodesix Announces Research Agreement with Top US Cancer Center

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research agreement (MSRA) with Memorial Sloan Kettering Cancer Center (MSK). In addition, the MSRA between MSK and Biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment of cancer.

Jun 01, 2022 06:00 am ET

Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9, 2022 at the Lowes Chicago Hotel in Chicago, IL.

May 17, 2022 06:00 am ET

Biodesix to Present at the H.C. Wainwright Global Investment Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.

May 12, 2022 06:00 am ET

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2022 International Conference. The meeting will take place May 13-18, 2022, in San Francisco, California.

May 11, 2022 06:00 am ET

Biodesix Announces First Quarter 2022 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for first quarter ended March 31, 2022 and provided a corporate update.

Apr 27, 2022 06:00 am ET

Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2022 before the open of trading on Wednesday, May 11. Biodesix’s management will host a conference call and webcast to discuss its financial resul

Apr 12, 2022 08:58 am ET

BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, New Drugs for Cancers, Glaucoma, and Autism

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: PolarityTE, Inc. (NASDAQ: PTE) Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Biodesix, Inc. (NASDAQ:...

Apr 12, 2022 08:30 am ET

Thinking about buying stock in Actinium Pharmaceuticals, BioCardia, Veru, Biodesix, or Aeglea Bio Therapeutics?

NEW YORK, April 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNM, BCDA, VERU, BDSX, and AGLE.

Apr 11, 2022 06:00 am ET

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the sale of 6,508,376 common shares on April 7, 2022 in a private placement offering that raised approximately $11.7 million in net proceeds to, among other things, fund the partial repayment of its existing term loan and general corpora

Mar 29, 2022 06:00 am ET

Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, “Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.” This peer-reviewed publication further validates the GeneStrat NGS test and the use of multiple classes of tumor markers in circulating free nucleic acid analysis as a surrogate for tumor tissue biopsies. i

Mar 14, 2022 06:00 am ET

Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights

Mar 07, 2022 04:01 pm ET

Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered into a purchase agreement for the issuance and sale of its common stock, from time to time, of up to $50 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor.

Mar 03, 2022 06:00 am ET

Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of Lung Cancer Meeting

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting. In this body of work, the PIR test provided two classifications of PIR-Not Resistant and PIR-Resistant predictive of likely response to immune checkpoint inhibitors (ICIs). The data showed that the Biodesix PIR test was predictive for survival outcomes when tested at baseline (HR=2.36, p=0.02) or 3 weeks after ICI treatment initiation (HR=3.53, p=0.001

Mar 01, 2022 06:00 am ET

Biodesix to Present at Cowen’s 42nd Annual Healthcare Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at Cowen’s 42nd Annual Healthcare Conference being held virtually March 7-9, 2022.

Feb 28, 2022 06:00 am ET

Biodesix to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021 before the open of trading on Monday, March 14. Biodesix’s management will host a conference call and webcast to discuss its fin

Feb 22, 2022 06:00 am ET

Biodesix CEO Scott Hutton Named to The Healthcare Technology Report’s List of Top 25 Biotech CEOs in 2022

Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that its Chief Executive Officer was named in The Healthcare Technology Report’s list of Top 25 Biotech CEOs of 2022. The annual list recognizes the most accomplished executives in the biotech industry.

Feb 14, 2022 06:00 am ET

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (Unaudited)

Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report fourth quarter and record full-year 2021 preliminary unaudited total revenue of $7.2 million and $54.5 million, respectively. The strength in the full-year 2021 total revenue of $54.5 million compared to $45.6 million in 2020 was a result of growth in the Company’s core lung diagnostic testing and first half 2021 COVID-19 testing. The financial results included in this release pertaining to the fourth quarter and year ended December 3

Feb 09, 2022 06:00 am ET

Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held virtually February 15-17, 2022.

Jan 19, 2022 09:15 am ET

PierianDx and Biodesix Partner to Advance Lung Cancer Diagnostics

PierianDx, the global leader in clinical genomics knowledge, today announced that it has partnered with Biodesix to provide its interpretation technology platform for use with the Biodesix newly launched GeneStrat NGS™ genomic test, a blood-based tumor profiling test to detect actionable mutations in patients with non-small cell lung cancer (NSCLC). Biodesix (N

Jan 18, 2022 06:00 am ET

Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today the national launch of its new GeneStrat NGS™ genomic test, a blood-based tumor profiling test. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced- stage lung cancer patients identif

Jan 04, 2022 04:01 pm ET

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the sale of 3,756,994 common shares on December 30, 2021 in an at-the-market offering that raised approximately $16.3 million in gross proceeds to fund repayment of its existing term loan.

Dec 08, 2021 06:00 am ET

Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company’s board of directors. Dr. Kayyem’s diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various l

Dec 01, 2021 06:00 am ET

Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer

Spesana, the developer of a novel electronic operating system to unify EMRs, and

Nov 18, 2021 06:00 am ET

Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) utilizing its

Nov 15, 2021 07:45 am ET

Biodesix Announces Third Quarter 2021 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the third quarter ended September 30, 2021 and provided a corporate update.

Nov 12, 2021 07:00 am ET

Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company will co-present with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), three posters at the 36th Annual Society for Immunotherapy of Cancer (SITC) Nov. 10 – 14, 2021 from research into diagnostic tests of treatment response of NSCLC patients to immune checkpoint inhibitor therapy.

Nov 11, 2021 06:00 am ET

Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021.

Nov 01, 2021 06:00 am ET

Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15. Biodesix’s management will host a conference call and webcast to discuss its financial

Oct 13, 2021 06:00 am ET

Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference. Presentations will include newly emerging data from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test - ORACLE [NCT03766958]), demonstrating that incorporation of this blood-based test in the management of patients with newly detected lung nodules modified physician behavior. The prospectively col

Sep 16, 2021 09:20 am ET

Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).

Sep 02, 2021 06:00 am ET

Biodesix to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat the Morgan Stanley Virtual 19th Annual Global Healthcare Conference being held virtually September 9-10 and September 13-15, 2021.

Aug 25, 2021 06:00 am ET

Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists

Biodesix, Inc. (Nasdaq: BDSX). Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ISO 13485:2016 certification to the Biodesix Laboratory located in D

Aug 10, 2021 04:01 pm ET

Biodesix Announces Second Quarter 2021 Results and Highlights

Aug 02, 2021 06:00 am ET

Biodesix to Present at the Canaccord Genuity 41st Annual Growth Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021.

Jul 27, 2021 06:00 am ET

Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the second quarter ended June 30, 2021 after the close of trading on Tuesday, August 10. Biodesix’s management will host a conference call and webcast to discuss its financial resu

Jun 17, 2021 04:01 pm ET

Biodesix Announces Presentation on Novel Proteomic Techniques in Partnership with Seer

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, a webinar to present the newest trends in proteomics for biomarker discovery and translational research. The webinar entitl

Jun 15, 2021 06:00 am ET

Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the broad commercial launch of a SARS CoV-2 Neutralization Antibody Test (cPass™ Neutralization Test Kit, GenScript Inc.). The test uses ELISA technology to detect circulating neutralizing antibodies against the receptor bi

Jun 04, 2021 09:00 am ET

Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank

Biodesix, a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, the leader in helping healthcare organizations safely connect their data. Datavant provides solutions to help protect, match, and share...

Jun 04, 2021 06:00 am ET

Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank

Biodesix, Inc. (Nasdaq: BDSX), a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their data. Datavant provides solutions to help protect, match, and share health data. Through this partnership, Biodesix will anonymize the lung cancer

May 25, 2021 06:00 am ET

Biodesix to Present at the William Blair 41st Annual Growth Stock Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 2021.

May 11, 2021 04:01 pm ET

Biodesix Announces First Quarter 2021 Results

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the first quarter ended March 31, 2021 and provided a corporate update.

Apr 28, 2021 06:00 am ET

Biodesix Announces Intent to Launch Liquid Biopsy Next Generation Sequencing Test with Unprecedented Turnaround Time

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, has announced their plan to add a blood-based 52-gene next generation sequencing (NGS) test to their portfolio of molecular testing based on a recent publication. Of critical importance, the publication, “

Apr 26, 2021 04:01 pm ET

Biodesix Announces Presentation on SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced in partnership with GenScript Biotech Corporation, a webinar to present novel data on the rapid detection of total SARS-CoV-2 neutralizing antibodies using cPass™ technology. Neutralizing antibodies may specifically block t

Apr 26, 2021 06:00 am ET

Biodesix to Report First Quarter 2021 Financial Results on May 11, 2021

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2021 after the close of trading on Tuesday, May 11. Biodesix’s management will host a conference call and webcast to discuss its financial results

Apr 22, 2021 06:00 am ET

Biodesix Announces Presentation on Use of Biomarker-Based Risk Assessment to Inform Lung Nodule Management

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a webinar to discuss biomarkers and risk assessment in lung nodule management. The virtual session, hosted by the American College of Chest Physicians® (CHEST) and led by Susan Garwood, MD, National Physician Dir

Apr 10, 2021 08:30 am ET

Biodesix Releases New Data at AACR on Proteomic Profiling to Help Guide Physician Treatment Strategies for NSCLC Patients

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be showcased at the 2021 American Association for Cancer Research (AACR) Annual Meeting being held virtually April 10-15, 2021 and May 17-21, 2021. Findings from thes

Apr 06, 2021 06:00 am ET

Biodesix Announces Issuance of Two U.S. Patents, Expands Coverage of Diagnostic Methods to Improve Care for Cancer Patients

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents that will enhance its ability to develop blood-based immunotherapy and pipeline testing strategies. These developments further improve Biodes

Mar 23, 2021 04:00 pm ET

Biodesix Announces Closing of New $30 Million Term Loan

Biodesix, Inc. (NASDAQ: BDSX; “Biodesix” or the “Company”) a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that it has closed on a new $30 million term loan (New Term Loan) which matures on March 1, 2026.

Mar 16, 2021 03:00 pm ET

Biodesix Announces Fourth Quarter and Full Year 2020 Results

Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

Mar 09, 2021 05:00 am ET

Biodesix to Report Fourth Quarter and Fiscal 2020 Financial Results on March 16, 2021

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of trading on Tuesday, March 16. Biodesix’s management will host a conference call and webcast to discuss its fi

Feb 25, 2021 06:30 am ET

Biodesix CEO Scott Hutton Selected as One of Top 25 Biotech CEOs of 2021

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutton, as one of the

Feb 16, 2021 06:30 am ET

Biodesix Partners with Chicago Public Schools for COVID-19 Testing to Safely Reopen Schools

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company has partnered with Chicago Public Schools (CPS) to provide antigen and Droplet Digital PCR (ddPCR)™ testing for Chicago Public School teachers and staff. The CPS testing program, which launched in January,

Feb 12, 2021 06:30 am ET

Biodesix to Participate in Two February Conferences

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that management will participate in two upcoming conferences: the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021, and the LifeSci Partners Precisio

Feb 09, 2021 06:30 am ET

Biodesix Publishes Data on New COVID-19 Artificial Intelligence (AI)-Based Algorithm for Use in Clinical Decision Support Systems

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a publication describing the development of a new AI-based COVID-19 algorithm and the important data from a related study. The paper, entitled, “

Feb 02, 2021 07:30 am ET

Scott Hutton of Biodesix Selected as USA Chief Executive Officer of the Year by CEO Monthly Magazine

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Chief Executive Officer Scott Hutton was

Jan 26, 2021 06:30 am ET

Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), scheduled for January 28-31, 2021. Findings

Jan 13, 2021 07:00 am ET

HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization

Biodesix, Inc. (Nasdaq: BDSX) today announced an agreement with

Jan 13, 2021 06:00 am ET

HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization

NEW YORK and BOULDER, Colo., Jan. 13, 2021 /PRNewswire/ -- HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced an agreement with Biodesix, Inc. (Nasdaq: BDSX) to further the development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic in future registrational trials in breast cancer for Imprime PGG programs. Terms of the partnership were not disclosed.

Jan 08, 2021 06:00 am ET

Biodesix Anticipates Strong Preliminary Fourth Quarter 2020 Revenue (unaudited)

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company expects to report record fourth quarter 2020 preliminary unaudited revenue in a range of $25 million to $27 million. The strength in the fourth quarter 2020 was a result of growth in the company’s COVID-19 testing services, lung diagnostic testing, and biopharma services. The financial results included in this release pertaining to all interim periods are unaudited and the financial results as of and for the three-month period ended December 31, 2020 are preliminary

Jan 06, 2021 06:00 am ET

Purdue Partners With Colorado Company to Offer Rapid Testing for Students Ahead of Spring 2021 Semester

Purdue University is partnering with a Colorado company led by a Purdue alum to offer rapid antigen COVID-19 testing for undergraduate, graduate and professional students taking classes on the West Lafayette campus who will be living off campus (not in the residence halls or in Fraternity, Sorority and Cooperative Life housing) during the spring 2021 semester.

Jan 05, 2021 06:00 am ET

Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Ryan Siurek has joined the company as Chief Accounting Officer reporting to Ms. Robin Harper Cowie, Chief Financial Officer.

Dec 23, 2020 06:00 am ET

Biodesix Initiates Biomarker Study to Affirm Nodify XL2® Test’s Importance in Clinical Decision Making

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, is proud to announce the launch and active recruitment of a first-in-class biomarker study aligned with the recommendations from the official 2018 American Thoracic Society (ATS)

Dec 15, 2020 06:00 am ET

Biodesix Study Shows Proprietary Device Collects, Separates, and Transports Blood at Ambient Temperature

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced publication of a peer-reviewed study supporting its patented blood collection device (BCD). The device is designed to streamline whole blood specimen collection and transportation to the laboratory while delivering diagnostic test results that are equiv

Dec 10, 2020 05:24 pm ET

Biodesix Announces Third Quarter 2020 Results and Provides Corporate Update

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the third quarter ended September 30, 2020 and provided a corporate update.

Dec 01, 2020 06:00 am ET

Biodesix Publishes Extended Analyses of the Nodify XL2® Lung Nodule Test

Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the company’s Nodify XL2® lung nodule test. The test supports clinical decision-making for suspicious nodules by more accurately identifying patients with a very low risk of malignancy

Oct 30, 2020 04:15 pm ET

Biodesix Announces Closing of Initial Public Offering

Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds to Biodesix, before deducting underwriting discounts and commissions, were approximately $72.0 million. The shares began trading on The Nasdaq Global Market on October 28, 2020, under the symbol “BDSX.”

Oct 28, 2020 05:00 am ET

Biodesix Announces Pricing of Initial Public Offering

Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on The Nasdaq Global Market on October 28, 2020, under the symbol “BDSX.” The offering is expected to close on October 30, 2020, subject to the satisfaction of customary closing conditions. In addition, Biodesix has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the initial public offering price, less underw

You are here

Biodesix Inc (OQ:BDSX)

Business Focus: Medical & Diagnostic Laboratories